Fig. 7

LINC00680 is a potential therapeutic target in ESCC. a, b, c, d, e, g, i, k, m, o KYSE510 and KYSE140 cells were transfected with negative control ASO (ASO NC) or ASO specifically targeting LINC00680 (ASO LINC00680) followed by RT-qPCR analysis (a, b), cell proliferation assay (c, d), colony formation assay (e, g), wound healing assay (i, k), and transwell assay (m, o). Scale bar: 50 µm. f, h, j, l, n, p Quantification of the number of colonies (f, h), the percentage of wound area (j, l), and the number of invasive cells (n, p). q Graphic illustration of ASO NC or ASO LINC00680 injection in nude mice. r Images of excised tumors as described in (q) are shown. s The average of the weight of tumors as shown in (r). (t) The growth curves of tumors as shown in (r). u, v The expression of LINC00680 (u) and PAK6 (v) in tumors as described in (r) was examined by RT-qPCR analysis. w A proposed model of LINC00680 function in ESCC. The highly expressed LINC00680 in ESCC cells functions as a miRNA sponge to sponge miR-423-5p to release its repression on PAK6, leading to the aberrant expression of PAK6 and ESCC tumorigenesis. The experiments were repeated for three times, and representative data is shown with mean ± standard deviation (SD), *P < 0.05, **P < 0.01, ***P < 0.001